Distinct molecular targets of ProEGCG from EGCG and superior inhibition of angiogenesis signaling pathways for treatment of endometriosis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Epigallocatechin gallate prodrug (ProEGCG) effectively treats endometriosis by targeting distinct pathways. ProEGCG inhibits angiogenesis via PXK, offering superior therapeutic effects compared to epigallocatechin gallate (EGCG).
Area Of Science
- Gynecology
- Molecular Biology
- Pharmacology
Background
- Endometriosis is a common gynecological disease driven by angiogenesis.
- Epigallocatechin gallate (EGCG) and its prodrug (ProEGCG) show anti-endometriotic effects, but mechanisms differ.
- Binding targets and pathways for ProEGCG's superior efficacy remain unclear.
Purpose Of The Study
- To identify binding targets of EGCG and ProEGCG.
- To elucidate the distinct anti-angiogenic mechanisms of EGCG and ProEGCG.
- To evaluate ProEGCG as a novel therapy for endometriosis.
Main Methods
- Chemical proteomics (1D and 2D Proteome Integral Solubility Alteration assay).
- Computational simulation and BioLayer interferometry for binding affinity.
- In vitro and in vivo knockdown assays and microvascular network imaging.
Main Results
- Metadherin (MTDH) identified as an EGCG target, inhibiting Akt-mediated angiogenesis.
- PX domain containing serine/threonine kinase-like (PXK) identified as a ProEGCG target, inhibiting EGF/HIF-1a/VEGF pathway.
- ProEGCG demonstrated superior anti-angiogenic and anti-endometriotic effects compared to EGCG.
Conclusions
- ProEGCG targets PXK, inhibiting the EGF/HIF-1a/VEGF pathway for superior anti-angiogenic effects.
- EGCG targets MTDH, inhibiting Akt-mediated angiogenesis.
- ProEGCG represents a promising novel antiangiogenic therapy for endometriosis.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...